$NRXP (Nasdaq) The Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share https://benzinga.com/pressreleases/24/07/ab40021653/accelerated-approval-to-treat-bipolar-depression-and-akathisia-could-yield-over-150-in-revenue-pe $GVSI $MULN $TSLA $PLUG